HY-1770

N/A

Report date: 2024/12/10 13:18:50
NME

Base Information

Drug NameHY-1770
Drug Alias NameHY-1770HY1770HT-17HT17YF02 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin 17A inhibitorsInterleukin-17F inhibitorsInterleukin-4 receptor subunit alpha inhibitors
TargetsInterleukin 17AInterleukin-17FInterleukin-4 receptor subunit alpha
Therapy Area/IndicationsPlaque psoriasisDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSuzhou Pharmavan Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSuzhou Pharmavan Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A